Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events

K. Liang Zeng, MD∗
Arjun Sahgal, MD O∗
Chia-Lin Tseng, MDCM∗
Sten Myrehaug, MD∗
Hany Soliman, MD∗
Jay Detsky, MD, PhD O∗
Eshetu G. Atenafu, MSc‡
Young Lee, PhD∗
Mikki Campbell, MRT(T), MHE∗
Pejman Maralani, MD§
Zain A. Husain, MD∗

∗Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; ‡Department of Biostatistics, University Health Network, University of Toronto, Toronto, Ontario, Canada; §Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

BACKGROUND: Patient selection is critical for spine stereotactic body radiotherapy (SBRT) given potential for serious adverse effects and the associated costs.

OBJECTIVE: To identify prognostic factors associated with dying within 3 mo, or living greater than 3 yr, following spine SBRT, to better inform patient selection.

METHODS: Patients living ≤3 mo after spine SBRT and >3 yr after spine SBRT were identified, and multivariable regression analyses were performed. We report serious late toxicities observed, including vertebral compression fractures (VCF) and plexopathy.

RESULTS: A total of 605 patients (1406 spine segments) were treated from 2009 to 2018. A total of 51 patients (8.4%) lived ≤3 mo, and 79 patients (13%) survived >3 yr. Significant differences in baseline features were observed. On multivariable analysis, nonbreast/prostate primaries (odds ratio [ORs]: 28.8-104.2, P = .0004), eastern cooperative oncology group (ECOG) ≥2 (OR: 23.7, 95% CI: 3.2-177, P = .0020), metastatic disease (OR: 6.715, 95% CI: 1.89-23.85, P = .0032), painful lesions (OR: 3.833-8.898, P = .0118), and paraspinal disease (OR: 2.874, 95% CI: 1.118-7.393, P = .0288) were prognostic for ≤3 mo survival. The 3- and 5-yr rates of VCF were 10.4% and 14.4%, respectively, and 3- and 5-yr rates of plexopathy were 2.2% and 5.1%, respectively. A single duodenal perforation was observed, and there was no radiation myelopathy events.

CONCLUSION: Shorter survival after spine SBRT was seen in patients with less radiosensitive histologies (ie, not breast or prostate), ECOG ≥2, and polymetastatic disease. Pain and paraspinal disease were also associated with poor survival. Fractionated spine SBRT confers a low risk of late serious adverse events.

KEY WORDS: Spine, Metastases, SBRT, Poor prognosis, Survival, Patient selection

Neurosurgery 0:1–9, 2021 DOI:10.1093/neuros/nyaa583 www.neurosurgery-online.com

T he spine is a common site of metastatic dissemination and can cause significant morbidity and mortality. Traditionally, conventional palliative external beam radiotherapy (cEBRT) with a low uniform dose was standard of care for metastatic spine disease, and associated with an overall and complete pain response rate of 60% to 70% and ~20%, respectively.1 Tumor control with palliative cEBRT is not well studied, as this was historically not an intent of treatment. In contrast, the goal of spine SBRT is local tumor ablation. SBRT requires millimetric precision to avoid overdosing neural structures, which can lead to devastating consequences, such as paralysis. Multiple series support high rates of local control from 80% to 95%, and excellent pain relief with a phase 2 trial reporting 40% complete pain response.2–4 Importantly, high rates of local control are observed even in radioresistant histologies, that previously exhibited poor response with cEBRT.5 With novel systemic agents, metastatic cancer patients are living

ABAVERIATIONS: cEBRT, conventional palliative external beam radiotherapy; CI, confidence interval; ECOG, eastern cooperative oncology group; SBRT, stereotactic body radiotherapy; SINS, Spinal Instability Neoplastic Score; VCF, vertebral compression fracture

Neurosurgery Speaks! Audio abstracts available for this article at www.neurosurgery-online.com.
Supplemental digital content is available for this article at www.neurosurgery-online.com.
longer making durable tumor and pain control achieved with SBRT an increasingly important objective.

SBRT requires significantly more resources including specialized equipment, additional planning, and treatment time, as well as expertise. This comes at considerable expense, and cost-effectiveness analyses estimate the treatment cost of single fraction SBRT to be 9-fold higher than cEBRT. Additionally, risk of adverse events such as vertebral compression fracture (VCF) and late neurological injury (myelopathy and peripheral nerve dysfunction) is higher. It is critical to ascertain which patients benefit most from more intensive treatment.

In surgical practice, a minimum prognosis of 3 mo is necessary to be considered for operative intervention, and the American Society for Radiation Oncology Evidence-Based Guideline also suggested a similar minimum 3-mo prognosis for SBRT. Lastly, specific to spine SBRT, the reporting of RTOG-0631 in abstract form challenges the application of spine SBRT to patients with 3-mo survival given the lack of symptomatic benefit compared to cEBRT at the 3-mo primary endpoint. As a result, there is a need to identify factors associated with a ≤3-mo survival to inform patient selection. The purpose of this study was to identify prognostic factors associated with ≤3 mo of life following spine SBRT, as compared to those surviving >3 yr. Additionally, we report late serious adverse effects, including VCF and brachial/lumbosacral plexopathy.

METHODS

Study Design

A prospectively maintained database of 605 patients (1406 spine segments) treated with spine SBRT, between January 2009 and December 2018, was reviewed (Figure 1). This study was approved by our Research Ethics Board, and consent was exempted because of the retrospective nature of this study. Patients who died ≤3 mo after SBRT and those who survived >3 yr were included. Demographics including gender, performance status, age, primary cancer, oligometastatic disease (≤5 metastases) or polymetastatic disease (>5 metastases), visceral and/or brain metastases, and treatment indication (de novo, postoperative, or retreatment) were collected. Radioresistant malignancies included renal cell carcinoma, sarcoma, melanoma, colorectal cancer, and thyroid cancer. Tumor factors including SINS (Spinal Instability Neoplastic Score), epidural grade, and presence of paraspinal disease along with dose fractionation were studied. Our treatment technique has been reported, and patients were followed per institutional protocol, including clinic assessment and full spine magnetic resonance imaging every 2 to 3 mo. We report serious adverse events in the 3-yr surviving cohort. Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Statistical Methods

Clinical factors were reported per patient and tumor factors per segment amongst each cohort. Logistic regression analysis was used to
assess for potential predictors of living ≤3 mo after spine SBRT. A generalized linear mixed model with binary outcome (living ≤3 mo vs >3 yr) was used to assess the impact of patient and tumor factors per spinal segment. Predictors with P-value < .02 on univariate analysis were selected for multivariable analysis. Analyses were performed for local control, considering death as competing risk. All P-values were 2-sided, and for the statistical analyses, a P < .05 was considered statistically significant. Analyses were performed using version 9.4 of the SAS system for Windows, 2002-2012 SAS Institute Inc (Cary, North Carolina).

RESULTS

Participants

A total of 52 and 79 patients, corresponding to 107 and 135 segments, respectively, survived ≤3 mo and >3 yr following spine SBRT (Table 1). The 52-patient cohort living ≤3 mo after spine SBRT represented a total of 8.4% of patients treated with spine SBRT, and the 79-patient cohort living >3 yr represented 12.7% of patients. Those with colorectal cancer had the highest proportion of patients living ≤3 mo (12/41 total colorectal cancer patients in the entire 605-patient cohort; Table 2). Features of patients with non small cell lung cancer and renal cell carcinoma receiving targeted therapy or immunotherapy are detailed in Table. Supplemental Digital Content. Median survival for those living ≤3 mo was 58 d (range: 11-91 d), and median follow-up for those living >3 yr was 4 yr (range: 3.0-8.6 yr). 67.3% of patients living ≤3 mo and 96.3% of patients surviving >3 yr were treated with 2 fraction regimens.

Baseline Patient and Tumor Factors

Many baseline factors were significantly different between groups (Table 1; Figures 2 and 3). No patient with breast cancer survived ≤3 mo after SBRT. Patients living ≤3 mo were more likely to have poor performance status, neurological deficits, radioresistant primary cancers, polymetastatic disease, and prior radiotherapy to the treatment site. Approximately 71% of those dying within 3 mo of treatment were eastern cooperative oncology group (ECOG) 0-1. These patients also had higher frequency of paraspinal disease, baseline VCF, and to be treated with more fractionated regimens.

Features Associated With Living ≤3 Months

On univariable analysis, polymetastatic disease, nonbreast or prostate primary cancer, lung/liver or brain metastases, ECOG performance status ≥2, male gender, poor neurological status, duration from diagnosis to treatment, pain, and paraspinal disease were statistically significant predictors of living ≤3 mo after spine SBRT. Age, treatment indication, presence of VCF, and epidural disease status were not significant.

On multivariable analysis (Table 3), nonbreast/prostate primary cancer (odds ratio [OR]: 104.18, 95% CI: >8.28, P = .0004), ECOG performance status ≥2 (OR: 23.7, 95% CI: 3.17-177, P = .0020), and polymetastatic disease (OR: 6.715, 95% CI: 1.891-23.849, P = .0032) were associated with living ≤3 mo after spine SBRT. Segments with paraspinal disease had higher risk dying ≤3 mo after spine SBRT (OR: 2.874, 95% CI: 1.118-7.393, P = .0288). Those with painful spinal lesions (as assessed by SINS) were more likely to die within 3 mo of treatment (OR: 3.833-8.898, P = .0118). There was a trend towards significance for presence of liver and/or lung metastases (OR: 4.063 and 5.863, P = .0556).

Local Control

In those who survived at least 3 yr, local failure at 3 yr was 12.5% (95% CI: 6.8%-18.3%), and at 5 yr was 14.4% (95% CI: 5.2%-23.6%). There was variation in local failure depending on histology, with radioresistant histologies at a greater risk with a 3-yr failure rate of 25% vs 7.2% for those breast/prostate metastases.

Early Deaths and Acute Serious Adverse Events

Three patients (5.8%) who lived ≤3 mo after spine SBRT died of causes potentially relating to spine disease. Two patients experienced neurological deterioration relating to progression of nontreated sites, one patient had a significant episode of flare of pain after treatment, and one patient had cardiac complications relating to dehydration.

Systemic Therapy in Those Living ≤3 Months

Almost half of the patients (47.1%) living ≤3 mo had received ≥2 lines of systemic therapy, and 45.8% had received ≥4 lines of systemic therapy prior to SBRT (Table 1). One patient had received 7 lines of systemic therapy; systemic therapy was administered to 66.7% of patients within 3 mo of death.

Late Toxicities

In patients living >3 yr, there were a total of 13 (9.6%) cases of new VCF and 6 (4.4%) of progression of existing VCFs (Figure 4). This occurred at a median of 24.0 mo after spine SBRT (range: 1.97-98.7 mo). The incidence of VCF was 2.2% at 1 yr, 7.4% at 2 yr, 10.4% at 3 yr, and 14.4% at 5 yr.

A total of 6 cases of plexopathy (1 brachial and 5 lumberosacral plexopathy) were observed (Table 4). These occurred at a median of 35.7 mo (range: 10.9-41.9 mo). Plexopathy at 1, 2, 3, and 5 yr was 0.74%, 1.5%, 2.2%, and 5.1%, respectively. Three patients had 3 courses of radiotherapy (cEBRT then SBRT twice) to the site of toxicity, 2 had 2 courses of SBRT, and a single patient had plexopathy after 1 course of SBRT. We observed a single case of duodenal perforation after 3 courses of SBRT to the same spinal site (2 spines and 1 para-aortic node close to the target spinal segment); this patient died ≤3 mo after spine SBRT. There were no cases of radiation myelopathy.

DISCUSSION

Key Results

With evolving technology and the ability to offer more aggressive palliative treatments, prognostication of survival is a
|                          | Died within 3 mo (n = 51) | Living longer than 3 yr (n = 79) | P value |
|--------------------------|--------------------------|-------------------------------|---------|
| **Gender**               |                          |                               |         |
| Female                   | 20 (39.2%)               | 48 (60.8%)                    | .0163   |
| Male                     | 31 (60.8%)               | 31 (39.2%)                    |         |
| **ECOG**                 |                          |                               |         |
| 0-1                      | 36 (70.6%)               | 75 (94.9%)                    | .0001   |
| ≥ 2                      | 15 (29.4%)               | 4 (5.1%)                      |         |
| **Age at diagnosis**     |                          |                               |         |
| Median (range)           | 69 (27.11-89)            | 67 (29-90)                    | .4864   |
| **Duration from diagnosis to treatment** | 1.53 (0.08-19.85) | 3.87 (0.05-27.86) | .0406 |
| **Neurological status**  |                          |                               |         |
| Normal                   | 40 (78.4%)               | 75 (94.9%)                    | .0048   |
| Abnormal                 | 11 (21.6%)               | 4 (5.1%)                      |         |
| **Primary cancer**       |                          |                               |         |
| Breast                   | 0 (0%)                   | 35 (44.3%)                    | <.0001  |
| Colon                    | 12 (23.5%)               | 2 (2.5%)                      |         |
| NSCLC                    | 16 (31.4%)               | 11 (13.9%)                    |         |
| Prostate                 | 3 (5.9%)                 | 20 (25.3%)                    |         |
| Renal                    | 11 (21.6%)               | 5 (6.4%)                      |         |
| Other                    | 9 (17.6%)                | 6 (7.6%)                      |         |
| **Histologic classification** |                      |                               |         |
| Radiosensitive           | 27 (52.9%)               | 68 (88.1%)                    | <.0001  |
| Radioresistant           | 24 (47.1%)               | 11 (13.9%)                    |         |
| **Oligometastatic disease** |                      |                               | <.0001  |
| Yes                      | 14 (27.5%)               | 63 (79.8%)                    |         |
| No                       | 37 (72.5%)               | 16 (20.2%)                    |         |
| **Previous surgery at site** |                      |                               | .2836   |
| Yes                      | 10 (19.6%)               | 10 (12.7%)                    |         |
| No                       | 41 (80.4%)               | 69 (87.3%)                    |         |
| **Previous RT at site**  |                          |                               |         |
| Yes                      | 14 (27.5%)               | 8 (10.1%)                     | .0101   |
| No                       | 37 (72.5%)               | 71 (89.9%)                    |         |
| **Brain metastases**     |                          |                               | .0103   |
| Yes                      | 13 (25.5%)               | 7 (8.9%)                      |         |
| No                       | 38 (74.5%)               | 72 (91.1%)                    |         |
| **Liver or lung metastases** |                      |                               | <.0001  |
| Both                     | 10 (19.6%)               | 5 (6.3%)                      |         |
| Liver                    | 9 (17.6%)                | 8 (10.1%)                     |         |
| Lung                     | 21 (41.2%)               | 9 (11.4%)                     |         |
| None                     | 11 (21.6%)               | 57 (72.2%)                    |         |
| **Treatment indication** |                          |                               | .0172   |
| De novo                  | 30 (58.8%)               | 62 (78.5%)                    |         |
| Postop                   | 5 (9.8%)                 | 8 (10.1%)                     |         |
| Retreat                  | 16 (31.4%)               | 9 (11.4%)                     |         |
| **Number of lines of systemic therapy** |                |                               | N/A     |
| 0-1                      | 27 (52.9%)               | N/A                           | N/A     |
| 2-3                      | 13 (25.5%)               |                               |         |
| 4-7                      | 11 (21.6%)               |                               |         |
| **Systemic therapy within 3 mo of data of death** |            |                               |         |
| Yes                      | 24 (66.7%)               | N/A                           | N/A     |
| No                       | 12 (33.3%)               |                               |         |
TABLE 1. Continued

| Location within spine | Segments treated in those that lived ≤3 mo (n = 107) | Segments treated in those living >3 yr (n = 135) | P value |
|-----------------------|-----------------------------------------------|-----------------------------------------------|---------|
| Cervical              | 18 (16.8%)                                    | 12 (8.9%)                                     | .9929   |
| Thoracic              | 51 (47.7%)                                    | 76 (56.3%)                                    |         |
| Lumbar                | 33 (30.8%)                                    | 34 (25.2%)                                    |         |
| Sacral                | 5 (4.7%)                                       | 13 (9.6%)                                     |         |
| Dose fractionation    |                                               |                                               |         |
| 18-24 Gy/1#           | 2 (1.9%)                                       | 0 (0%)                                        | <.0001  |
| 20-28 Gy/2#           | 72 (67.3%)                                     | 130 (96.3%)                                   |         |
| 24 Gy/3#              | 3 (2.8%)                                       | 1 (0.7%)                                      |         |
| 30 Gy/4-5#            | 30 (28.0%)                                     | 4 (3.0%)                                      |         |
| Paraspinal extension  |                                               |                                               | .5513   |
| Yes                   | 56 (52.3%)                                     | 31 (22.0%)                                    |         |
| No                    | 51 (47.7%)                                     | 104 (77.0%)                                   |         |
| Bilsky epidural grade |                                               |                                               | .8876   |
| 1A                    | 9 (16.7%)                                      | 10 (26.3%)                                    |         |
| 1B                    | 15 (27.8%)                                     | 7 (18.4%)                                     |         |
| 1C/2/3                | 30 (55.3%)                                     | 21 (55.3%)                                    |         |
| SINS classification    |                                               |                                               | .9449   |
| Stable                | 40 (37.4%)                                     | 81 (60.0%)                                    |         |
| Potentially unstable  | 57 (53.3%)                                     | 49 (36.3%)                                    |         |
| Unstable              | 10 (9.3%)                                      | 5 (3.7%)                                      |         |
| Baseline VCF          |                                               |                                               | .7259   |
| Yes                   | 35 (32.7%)                                     | 23 (17.0%)                                    |         |
| No                    | 72 (67.3%)                                     | 112 (83.0%)                                   |         |

NSCLC: non small cell lung cancer; RCC: renal cell carcinoma.
Bold signifies statistical significance.

Critical component in decision-making. The appropriateness of spine SBRT should be considered within this context. Physician prognostication based on experience and clinical acumen alone can be inaccurate, and quantification and modeling of data can often be of aid in this process. We observed that 8.4% of patients lived ≤3 mo of spine SBRT. These patients tended to have nonbreast/prostate histology, poor performance status, polymetastatic disease, painful lesions, and paraspinal disease.

Interpretation

Within our cohort, challenges in patient selection and physician prognostication are also observed in the decision for active systemic therapy. Two-thirds of those patients who lived ≤3 mo from the time of spine SBRT also received systemic therapy (cytotoxic chemotherapy, immunotherapy, or targeted nonhormonal oral agents). This illustrates that these patients were not in hospice and deemed by multiple physicians fit to receive aggressive palliative treatments, reinforcing the need for better modeling of survival to spare these patients potentially toxic treatments in their last months of life.

Nonbreast/prostate primary cancers, poor performance status, extensive metastatic disease, pain, and paraspinal disease were predictive of living ≤3 mo after spine SBRT. Patients with breast and prostate cancer typically exhibit slower disease progression with longer survival. Recent major trials in metastatic breast cancer demonstrate survival of 58% at 3.5 yr and in metastatic prostate cancer, 3-yr survival of 80%. Given prolonged survival in these patients, long-term local control is important and supports the use of SBRT in this group of favorable risk patients. Ongoing clinical trials will inform this endpoint along with long-term pain control, as 3-mo pain control has historically been the primary outcome of interest. Performance status reflects function, which implicates treatment tolerability and independently predicts survival. In prior spine SBRT series, poor performance status is consistently identified as a feature of patients with poor prognosis. This is only a component of survival prediction, as reflected by 71% of those dying ≤3 mo of treatment being ECOG 0-1. Interest in defining an oligometastatic state has increased, with evidence suggesting focal therapies to limited metastatic disease yields better survival and progression outcomes.
with polymetastatic disease were more likely to live ≤3 mo after treatment. To our knowledge, tumor factors have not previously been included as part of survival outcomes after spine SBRT. Patients with paraspinal disease and painful metastases were more likely to have shorter survival. Paraspinal disease may reflect a greater burden of disease in the spine and potentially reflect biologically more aggressive disease. In the surgical realm, pain has been associated with poor survival and may contribute to poor performance status because of symptom burden.21,22 In Pointillart et al’s prospective study spine surgery for metastatic disease, pretreatment pain scores ≥6 determined by self-assessment on a 0 (no pain) to 10 (worst pain) scale were associated with worse survival after surgery (hazard ratio 1.988, \( P = .0134 \)). We are unable to comment on pain response to treatment, which may better support this hypothesis, and ongoing randomized clinical trials may inform this endpoint.

**Generalizability**

Two indices have been developed to aid decision making in spine SBRT. A recursive partitioning analysis identified 3 factors that were most prognostic for survival—age, performance status, and time from diagnosis.16 This study also identified a difference in survival based on radioresistant breast/prostate and other histologies. The Prognostic Index for Spinal Metastases outlines groups that would most benefit from spine SBRT.17,18 This factors gender, performance status, previous surgery and previous radiotherapy, other visceral metastases, and time from diagnosis to metastasis. Our findings are consistent and utilize a strict ≤3 mo survival cutoff that has historically been suggested to

| Patients treated (total = 605 patients) | Number of patients who live ≤3 mo (as percent of total patients treated with that histology) | Number of patients who live >3 yr (as percent of total patients treated with that histology) |
|----------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Breast cancer                          | 120                                                                                             | 0 (0%)                                                                                           | 35 (29.2%)                                                                                     |
| Prostate cancer                        | 98                                                                                              | 3 (3.1%)                                                                                         | 20 (20.4%)                                                                                     |
| Colorectal cancer                      | 41                                                                                              | 12 (29.3%)                                                                                       | 2 (4.9%)                                                                                        |
| NSCLC                                  | 113                                                                                             | 16 (14.2%)                                                                                       | 11 (9.7%)                                                                                      |
| Renal cell carcinoma                   | 104                                                                                             | 11 (10.6%)                                                                                       | 5 (4.8%)                                                                                       |
| Melanoma                               | 20                                                                                              | 1 (5.0%)                                                                                         | 2 (10.0%)                                                                                      |
| Thyroid cancer                         | 12                                                                                              | 0 (0%)                                                                                           | 2 (16.2%)                                                                                      |
| Other\(^a\)                            | 97                                                                                              | 8 (8.2%)                                                                                         | 2 (2.1%)                                                                                       |

\(^a\)Other includes histologies such as anal canal cancer, bladder/urothelial cancer, esophageal cancer, endometrial cancer, cervix cancer, primary head and neck cancers, primary skin cancer, sarcoma, and unknown primary cancers.
be the absolute minimal prognosis to benefit from more intensive treatment such as surgery, and such a cutoff should be used for advanced radiotherapy techniques such as SBRT.

In the surgical setting, patient selection is critical because of potential for immediate morbidity and mortality. Verlaan et al. evaluated characteristics of 1266 patients undergoing spine surgery for metastatic spinal disease. Those living ≤3 mo had worse performance status and were older, whereas those with longer survival had lower spinal disease burden and favorable tumor histology. In their series, 84% of patients who died ≤3 mo of surgery died because of progression of the malignant process rather than surgical complications. Radiotherapy may be advantageous here, where patients can start systemic therapy sooner. Dea et al. reviewed 253 patients undergoing surgery for spinal metastases and compared those with survivals less than and greater than 3 mo. Those surviving ≤3 mo after had worse baseline performance status, pain, and quality of life.

### Toxicties

The rate of VCF at 3 yr was 10.4% and plexopathy 2.2%. Peripheral nerve injury occurred between 11 and 42 mo (median: 36 mo) after the initial course of SBRT, and 5 of 6 patients were exposed to more than one course of radiotherapy. Stubblefield et al. reported 14 similar events amongst 557 segments treated with SBRT amongst 447 patients. These patients received between 18 and 26 Gy in a single fraction, whereas our usual de novo regimen is 24 Gy in 2 fractions or 30 Gy in 4 to 5 fractions when retreating or in the presence of large bulky volumes. The tolerance of peripheral nerves to SBRT dose fractionations is poorly understood and given potential devastating neurological sequelae, warrants further study. VCF was expected and our rate is consistent with the literature. No radiation myelopathy was observed. A single duodenal perforation was observed that was nonfatal and occurred after multiple courses of SBRT to the same spinal segment.

### Limitations

We are limited by the relatively low number of deaths within 3 mo of SBRT and those who survived longer than 3 yr. Secondly, we are unable to quantify systemic therapy time factors such as duration of response, which undoubtedly influences prognosis. Lastly, death is often multifactorial, and comorbidities contribute towards the success and availability of life-sustaining measures towards end of life. We attribute 3 deaths to progression of spine disease itself. Cause of death was generally because of overall progression of disease. The Charlson index may be informative as it has been reported as the strongest predictor of survival after surgery for spinal metastases.

### Conclusion

Overall, within a large cohort of over 600 patients including over 1400 segments treated with spine SBRT, 8.4% of patients die within 3 mo of treatment. Patients with less radiosen-

---

**TABLE 3. Multivariable Analysis for Predictors of Dying ≤3 Months After Receiving Spine SBRT**

| Predictor                                    | Overall P value | Specific P value | OR   | 95% CI Lower | 95% CI Upper |
|-----------------------------------------------|-----------------|------------------|------|--------------|--------------|
| Presence of widespread metastases (non-oligometastatic) | .0032           | .0032            | 6.715| 1.891        | 23.849       |
| Lung cancer vs breast/prostate               | .0004           | -.0001           | 31.138 | 4.797       | 202.122      |
| Nonbreast/prostate vs breast/prostate        | .02693          | .0001            | 104.184 | 8.282       | >999.999     |
| Radioresistant histology vs breast/prostate  | .0242           | .0242            | 28.839 | 4.913       | 169.291      |
| Presence of liver metastases                 | .0556           | .0556            | 4.063 | 0.850        | 19.415       |
| Presence of lung metastases                  | .1136           | .1136            | 5.863 | 1.290        | 26.644       |
| ECOG ≥2                                      | .0020           | .0020            | 23.697 | 3.172       | 177.011      |
| Pain free lesion (vs occasional pain)        | .0118           | .0118            | 3.833 | 1.222        | 12.029       |
| Pain free lesion (vs other)                  | .0048           | .0048            | 8.898 | 1.978        | 40.02        |
| Paraspinal disease                           | .0288           | .0288            | 2.874 | 1.118        | 7.393        |

---

**FIGURE 4. Cumulative incidence of vertebral compression fracture (VCF) and plexopathy (PLEX) after spine SBRT with number at risk.**

---
sitive histologies (ie, not breast or prostate), ECOG ≥2, and polymetastatic disease had shorter survival after spine SBRT. Other factors such as presence of paraspinal disease and painful metastases represent further tumor-related factors to consider when selecting patients for spine SBRT. Late serious toxicities such as plexopathy are rare and were observed predominantly in heavily radiated patients, even in patients surviving several years after spine SBRT.

Funding
This study did not receive any funding or financial support.

Disclosures
The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Sahgal is an advisor/consultant with Abbvie, Merck, Roche, Varian (Medical Advisory Group), Elekta (Gamma Knife Icon), BrainLAB, and VieCure (Medical Advisory Board); a board member for International Stereotactic Radiosurgery Society (ISRS); has had past educational seminars with Elekta AB, Accuray Inc, Varian (CNS Teaching Faculty), BrainLAB, and Medtronic Kyphon; received research grants with Elekta AB and travel accommodations/expenses by Elekta, Varian, BrainLAB; and belongs to the Elekta MR Linac Research Consortium, Elekta Spine, and Oligometastases and Linac Based SRS Consortia. Dr Husain has received travel accommodations from Elekta AB.

REFERENCES
1. Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126(3):547-557.
2. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71(2):484-490.
3. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastases and its pattern of failure. J Neurosurg Spine. 2007;7(2):151-160.
4. Gerstene PC, Burton SA, Orhasoglu C, Welch WC. Radiosurgery for spine metastases: clinical experience in 500 cases from a single institution. Spine. 2007;32(2):193-199.
5. Zeng KL, Tseng C-L, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic body radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol. 2019;9:357.
6. Kim H, Rajagopalan MS, Beriwal S, Huq MS, Smith KJ. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Int J Radiat Oncol Biol Phys. 2015;91(3):556-563.
7. Verlaan J-J, Choi D, Versteeg A, et al. Characteristics of patients who survived < 3 months or > 2 years after surgery for spinal metastases: can we avoid inappropriate patient selection? J Clin Oncol. 2016;34(25):3054-3061.
8. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4-12.
9. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976.
10. Ryu S, Deshmukh S, Timmerman RD, et al. Radiosurgery compared to external beam radiotherapy for localized spine metastasis: phase III results of NRG Oncology/RTOG 0631. Int J Radiat Oncol Biol Phys. 2019;105(1):S2-S3.
11. Hyde D, Lochray F, Korol R, et al. Spine stereotactic body radiotherapy utilizing cone-beam CT image-guidance with a robotic couch: intrafraction motion analysis accounting for all six degrees of freedom. Int J Radiat Oncol Biol Phys. 2012;82(3):e555-e562.
12. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195-198.
13. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-524.
14. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121-131.
15. Buccheri G, Ferrigno D, Tamburini M, Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32(7):1135-1141.
16. Chao ST, Koyfman SA, Woody N, et al. Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):1738-1743.

17. Jensen G, Tang C, Hess KR, et al. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery. J Radiosurgery SBRT. 2017;5(1):25-34.

18. Tang C, Hess K, Bishop AJ, et al. Creation of a prognostic index for spine metastasis to stratify survival in patients treated with spinal stereotactic radiosurgery: secondary analysis of mature prospective trials. Int J Radiat Oncol Biol Phys. 2015;93(1):118-125.

19. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682.

20. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet. 2019;393(10185):2051-2058.

21. Pointillart V, Vital J-M, Salmi R, Diallo A, Quan GM. Survival prognostic factors and clinical outcomes in patients with spinal metastases. J Cancer Res Clin Oncol. 2011;137(5):849-856.

22. Hosono N, Ueda T, Tamura D, Aoki Y, Yoshikawa H. Prognostic relevance of clinical symptoms in patients with spinal metastases. Clin Orthop Relat Res. 2005;436:196-201.

23. Dea N, Versteeg AL, Sahgal A, et al. Metastatic spine disease: should patients with short life expectancy be denied surgical care? An international retrospective cohort study. Neurosurgery 2020;87(2):303-311.

24. Stubblefield MD, Ibanez K, Riedel ER, et al. Peripheral nervous system injury after high-dose single-fraction image-guided stereotactic radiosurgery for spine tumors. Neurosurg Focus. 2017;42(3):E12.

25. Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 2013;14(8):e310-e320.

26. Sprave T, Verma V, Förster R, et al. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases—a randomized controlled trial. BMC Cancer. 2018;18(1):859.

27. Arrigo RT, Kalanithi P, Cheng L, et al. Predictors of survival after surgical treatment of spinal metastasis. Neuromurgy. 2011;68(3):674-681, 681.

Supplemental digital content is available for this article at www.neurosurgery-online.com.

Supplemental Digital Content. Table. Breakdown of patients with NSCLC and RCC by cohort, who received targeted therapy or immunotherapy.

**COMMENT**

In this large single center retrospective study of prospectively collected data, the authors aim to identify factors associated with dying within 3 mo or living more than 3 yr after SBRT treatment. They found that nonfavorable histologies (nonbreast/prostate primaries), poor performance status, widespread metastatic disease, painful lesions and paraspinal disease was associated with short survival.

Their results support data from surgical series where poor performance status is consistently associated with short survival. Proper patient selection is crucial when using more invasive and costlier treatment like surgery and SBRT. As opposed to surgery, which can immediately improve stability, neurology or pain, the main goal of SBRT is towards better local control rates and thus might be futile in someone with poor survival, especially considering the added resources, time, and cost of SBRT compared to conventional radiation therapy and similar short term pain control.

As this treatment modality is increasingly utilized in many centers, another key message of this paper is their much-needed description of the late toxicities associated with SBRT. Vertebral compression fractured occurred in 10.4% at 3 yr, which is lower than previously reported. No radiation myelopathy and a very low rate of plexopathy (2.2% at 3 yr) was reported, even in long survivors which will definitely support the use of this treatment modality to increase local control in patients expected to outlive local control conferred by conventional techniques.

Nicolas Dea
Vancouver, British Columbia, Canada